DROSPIRENONE AND ETHINYL ESTRADIOL- drospirenone and ethinyl estradiol kit

Country: United States

Language: English

Source: NLM (National Library of Medicine)

Active ingredient:

DROSPIRENONE (UNII: N295J34A25) (DROSPIRENONE - UNII:N295J34A25), ETHINYL ESTRADIOL (UNII: 423D2T571U) (ETHINYL ESTRADIOL - UNII:423D2T571U)

Available from:

Nivagen Pharmaceuticals, Inc.

INN (International Name):

DROSPIRENONE

Composition:

DROSPIRENONE 3 mg

Prescription type:

PRESCRIPTION DRUG

Therapeutic indications:

Drospirenone and ethinyl estradiol tablets are indicated for use by women to prevent pregnancy. Do not prescribe drospirenone and ethinyl estradiol tablets to women who are known to have the following: - Renal impairment - Adrenal insufficiency - A high risk of arterial or venous thrombotic diseases. Examples include women who are known to: Smoke, if over age 35[see Boxed Warning and Warnings and Precautions (5.1)] Have deep vein thrombosis or pulmonary embolism, now or in the past[see Warnings and Precautions (5.1)] Have cerebrovascular disease[see Warnings and Precautions (5.1)] Have coronary artery disease[see Warnings and Precautions (5.1)] Have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation)[see Warnings and Precautions (5.1)] Have inherited or acquired hypercoagulopathies[see Warnings and Precautions (5.1)] Have uncontrolled hypertension[see Warnings and Precautions (5.5)] Have d

Product summary:

Drospirenone and ethinyl estradiol tablets contain 28 tablets in a blister card (NDC 75834-115-84). Each blister card contains, in the following order, 21 yellow tablets and 7 white tablets. Each round, biconvex, yellow tablet (debossed with "Y2" on one side) contains 3 mg drospirenone (DRSP) and 0.03 mg ethinyl estradiol (EE). Each round, biconvex, white tablet (debossed with "P" on one side and "N " on the other side) contains inert ingredients. Drospirenone and ethinyl estradiol tablets are available in the following packaging configuration: Carton of 3 blister cards        NDC 75834-115-29 Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].

Authorization status:

Abbreviated New Drug Application

Summary of Product characteristics

DROSPIRENONE AND ETHINYL ESTRADIOL - DROSPIRENONE AND ETHINYL
ESTRADIOL
NIVAGEN PHARMACEUTICALS, INC.
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
DROSPIRENONE AND ETHINYL
ESTRADIOL TABLETS SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING
INFORMATION FOR DROSPIRENONE AND
ETHINYL ESTRADIOL TABLETS
DROSPIRENONE AND ETHINYL ESTRADIOL TABLETS, 3 MG/0.03 MG, FOR ORAL USE
INITIAL U.S. APPROVAL:2001
WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS
_SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._
WOMEN OVER 35 YEARS OLD WHO SMOKE SHOULD NOT USE DROSPIRENONE AND
ETHINYL ESTRADIOL TABLETS. (4).
CIGARETTE SMOKING INCREASES THE RISK OF SERIOUS CARDIOVASCULAR EVENTS
FROM COMBINATION ORAL
CONTRACEPTIVE (COC) USE. (4)
RECENT MAJOR CHANGES
Contraindications (4) 08/2017
Warnings and Precautions (5.5) 08/2017
INDICATIONS AND USAGE
Drospirenone and ethinyl estradiol tablets are an estrogen/progestin
COC indicated for use by women to prevent
pregnancy. (1)
DOSAGE AND ADMINISTRATION
Take one tablet daily by mouth at the same time every day. (2.1)
Tablets must be taken in the order directed on the blister pack. (2.1)
DOSAGE FORMS AND STRENGTHS
Drospirenone and ethinyl estradiol tablets consist of 28 film-coated,
biconvex tablets in the following order (3):
21 yellow tablets, each containing 3 mg drospirenone (DRSP) and 0.03
mg ethinyl estradiol (EE)
7 white inert tablets
CONTRAINDICATIONS
Renal impairment (4)
Adrenal insufficiency (4)
A high risk of arterial or venous thrombotic diseases (4)
Undiagnosed abnormal uterine bleeding (4)
Breast cancer or other estrogen- or progestin-sensitive cancer (4)
Liver tumors or liver disease (4)
Pregnancy (4)
Co-administration with Hepatitis C drug combinations containing
ombitasvir, paritaprevir/ritonavir, with or without
dasabuvir (4)
WARNINGS AND PRECAUTIONS
Vascular risks : Stop drospirenone and ethinyl estradiol tablets if a
thrombotic event occurs. Stop at least 4 weeks
before and through 2 weeks after